Pharma Journalist -

Samsung BioLogics (SBL) and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB's anti-tau candidate to treat progressive…
Read More...

The U.S. Food and Drug Administration (FDA) approved Nubeqa (darolutamide), an androgen receptor inhibitor (ARi), for the treatment of patients with non-metastatic castration-resistant…
Read More...

Pfizer Inc. announced the closing of its joint venture with GlaxoSmithKline plc to combine the parties’ respective consumer healthcare businesses to create the world’s largest…
Read More...

Endo International plc announced the appointment of Domenic Ciarico as Executive Vice President and Chief Commercial Officer, Sterile and Generics, effective immediately. In this…
Read More...

Marken announced the acquisition of PCX International Co. Ltd based in Japan. PCX operates from their Tokyo headquarters to coordinate the delivery of over 3,000 clinical trial…
Read More...

Pfenex Inc. and Arcellx, Inc. announced a Development, Evaluation and License agreement under which Arcellx gains access to the proprietary Pfenex Expression Technology platform to…
Read More...

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced that the University of Delaware, on behalf of NIIMBL, has entered into a Collaborative…
Read More...

Cambrex Corporation announced that it is expanding its solid form screening and crystallization process development facility in Edinburgh, Scotland, doubling the current footprint to…
Read More...

NeoGenomics, Inc. and Pharmaceutical Product Development, LLC (PPD) announced the grand opening of a NeoGenomics oncology-focused clinical trials testing lab in the same building as the…
Read More...

Novartis announced Kisqali (ribociclib) achieved statistically significant improvement in overall survival in the Phase III MONALEESA-3 clinical trial. This is the second Phase III…
Read More...